OR WAIT null SECS
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
The new facility, which is expected to be operational by spring 2025, will feature 8 x 20,000-L bioreactors with the potential to add further 24 x 20,000-L bioreactors based on market demand.
Fujifilm announced on March 19, 2021 that it has selected Holly Springs, NC, as the location for its new $2-billion North American large-scale cell culture production site.
The new facility, which is expected to be operational by spring 2025, will feature 8 x 20,000-L bioreactors with the potential to add further 24 x 20,000-L bioreactors based on market demand, Fujifilm said in a company press release. The facility will also offer commercial scale, automated fill-finish and assembly, packaging, and labeling services.
“Holly Springs, North Carolina is a suitable location for us, as it is one of the most active communities in the [United States] in addressing environmental and social issues,” said Kenji Sukeno, president of Fujifilm, in the press release. “Fujifilm will contribute to realizing a sustainable society by collaborating with the Holly Springs community and stimulating the local economy. The new site is strategically important to accelerate the growth of our bio CDMO [contract development and manufacturing organization] business.”
“We are passionate about the tremendous value that this new facility will bring to our partners in producing life-impacting therapies. To build what will be the largest end-to-end cell culture CDMO facility in North America requires commitment and partnership. We are delighted to have received the strong support from the town of Holly Springs and the state of North Carolina. This is building for the future, both in infrastructure and in talent, as part of the vibrant North Carolina biotech hub,” added Martin Meeson, CEO of Fujifilm Diosynth Biotechnologies, in the press release.